SOLICITATION NOTICE
Q -- Discover diabetes metabolomics biomarkers in plasma and tissue samples
- Notice Date
- 5/18/2018
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NIHHL201800009
- Archive Date
- 6/8/2018
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- COMBINED SYNOPSIS SOLICITATION SOLICITATION NUMBER: NIHHL201800009 (i) "This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued." (ii) The solicitation number is NIHHL201800009 and the solicitation is being posted as a request for proposal (RFP). (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-97, January 24, 2018. (iv) This is small business set-aside, the associated NAICS Codes: 541380, Testing Laboratories and small business size standard is $15.0M. The acquisition is being conducted in accordance with the procedures of FAR Part 12 and FAR Part 13. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency. Offers are due by 7:30 A.M. Eastern Time (EST) on May 24, 2018. Responses must be submitted via email to Dorothy Maxwell, Contracting Officer at maxwelld@mail.nih.gov, I can be reached at (301)827-7729. (v) Background: The National Institutes of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Human Genome Research Institute (NHGRI), mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. A critical part of the NHGRI mission continues to be the study of the ethical, legal and social implications (ELSI) of genome research. The Medical Genomics and Metabolic Genetics Branch/Molecular Genetics Section Investigators use a broad range of tools to understand how health and disease are related to genetic, genomic and metabolic variation. Investigators study a broad spectrum of disorders, from common diseases associated with common variants to the rarest diseases associated with uncommon, sometimes unique variants. Scientific Investigators sometimes study disorders that are not inherited at all, which are due to somatic mosaicism-a difference in genetic composition among cells in an individual. Additionally, also study how the genome influences normal metabolic processes. MGMGB investigators apply tools ranging from high-throughput biology to clinical and animal research. A unifying theme in research is that the human is the most complex, fascinating and important system in which one can study the effects of heritable variation. For twenty years, NHGRI have been engaged in a large collaborative study entitled FUSION (Finland United States Investigation of NIDDM), in which more than 30,000 individuals with type 2 diabetes (T2D) (and suitable controls) from Finland are being studied. To achieve the objectives of the diabetes research the National Institute of Human Genome Research (NHGRI), Medical Genomics and Metabolic Genetics Branch (MGMGB) are initiating a translational research program extending the genetic association of T2D related genes to the functional analysis of these genes and the effects of the genetic background of normal vs. T2D subjects in tissues relevant to T2D. Towards this goal the FUSION project has collected skeletal muscle and adipose samples from ~100 normal glucose tolerant, ~100 impaired glucose response and 78 newly diagnosed T2D subject prior to medication. This allows the functional analysis of gene expression correlation with disease state and genetic background of the subjects. Purpose and Objectives: The purpose of the procurement is to study global metabolomics in the muscle and adipose tissue samples and well as global metabolomics plus complex lipids analyses in plasma collected during four-point glucose stimulated insulin secretion (GSIS) assay performed on the subjects two weeks prior to the tissue biopsy to correlate plasma circulating metabolites with metabolite content of the tissues under normal glucose tolerant (NGT) and T2D condition. With foresight towards integrating genetic and epigenetic analyses of subjects and their tissue samples in comparison to their metabolic phenotype as ascertained in the muscle, adipose tissue and plasma collected for the FUSION Tissue Biopsy Study. The comprehensive scope of metabolomic data required for these analyses includes but is not limited to biochemicals (peptides, enzymes and other protein components), complex lipids, triglycerides and free fatty acids as well as small metabolites. Procurement: 1. The Contractor will conduct Global Metabolomics (HD4) on muscle tissue samples (n=290), adipose tissue samples (n=271), and Global Metabolomics (HD4) and Complex Lipid (CLP) platforms on diabetes metabolomics biomarkers in plasma samples (n = 736) from NHGRI FUSION project. Anticipated Period of Performance : Base Year: May 2018 to May 2019 Contractor' Requirement : The Government's minimum requirements are as follows: • The Contract shall present sufficient capacity to analyze global metabolomics plus complex lipids in ≥736 plasma samples plus global metabolomics in ≥290 muscle samples and ≥271 adipose samples in 6-9 months. • The Contractor shall provide in depth [capacity to identify up to several thousand metabolites, known (uniquely named and unnamed)] and high throughput analysis (large sample size analysis) for plasma, muscle and adipose biological samples. • The Contractor shall be proficient at detection and identification of small molecule metabolites of over 60 different chemical classes in plasma, muscle and adipose tissue. • The Contractor shall be capable of performing no less than four different ultra-high-performance liquid chromatography/tandem accurate mass spectrometry (UHPLC/MS/MS) methods with peak identification, deconvolution, and chemical intelligence to identify metabolites. • The Contractor shall be capable of comparing assessed metabolites to chemical reference library of more than 4,000 known and 8,000 novel metabolites, allowing for rapid and accurate metabolite identification. • The Contractor shall provide comprehensive metabolite spectrum data compatible with Finnish METabolic Syndrome In Men (METSIM) Study to enable valid meta-analysis of metabolomics results. • The Contractor shall provide comprehensive named biochemical assayed, known information from public databases (KEGG/HMDB), and relative quantitation of metabolites in each tissue and plasma sample. • The Contractor shall provide comprehensive information on unnamed biochemical moieties detected I the global metabolomics and complex lipid analyses. • The Contractor shall provide documentation of the process of generating metabolomics data including internal reference controls and subsample replicates of tissue and plasma samples provided as well as the raw data generated in the analyses. • The Contractor shall provide regular written reports and ad hoc conference call updates throughout the analysis process. Deliverables: The Contractor shall deliver the following: 1. The Contractor shall deliver comprehensive metabolite analysis of muscle adipose and plasma derived from four different ultra-high-performance liquid chromatography/tandem accurate mass spectrometry (UHPLC/MS/MS) methods with peak identification, deconvolution, and chemical intelligence to identify metabolites returning all known and novel metabolites identified by reference libraries. Results are to be compatible with existing data generated Finnish METabolic Syndrome In Men (METSIM) Study to enable valid meta-analysis of metabolomics results. 2. The Contractor shall deliver comprehensive complex lipid analysis of matched plasma samples providing absolute quantitation of 14 lipid classes, in including principle phospholipid, sphingolipid and neutral lipid classes with molecular species concentrations and complete fatty acid composition of each lipid class. 3. The Contractor shall deliver data analysis include complex statistical analysis of differential metabolite and lipid content between sample subgroups and comprehensive biochemical association and enrichment analysis in reference biochemical databases (KEGG/HGMD). EVALUATION OF PROPOSALS: The Government will evaluate proposals that are determined technically acceptable in accordance with the Technical Evaluation factors. The Government intends to award a single contract from this solicitation. The Government reserves the right not to award a contract. Evaluation of Proposals: The Government reserves the right to make an award without discussions based solely upon initial proposals. Price (This will be Firm-Fixed Price): An evaluation of the offeror's price proposal will be made to determine if proposed prices are realistic for the work to be performed, reflect a clear understanding of the requirements, and are consistent with the technical proposal. Reasonableness determinations will be made by determining if competition exists, by comparing proposed prices with established commercial or GSA price schedules (if applicable), and/or by comparing proposed prices with the Independent Government Cost Estimate (IGCE). EVALUATION FACTORS: The evaluation will be based on the following : 1. Lowest price technically acceptable (LPTA). vi. The FAR Provision 52.212-1, Instructions to Offerors -- Commercial, applies to this acquisition and is hereby incorporated by reference. All Federal Acquisition Regulations (FAR) clauses may be viewed at http://acquisition.gov/comp/far/index.html. The proposal must reference the RFP Number: NIHHL201800009. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency. ix. In accordance to FAR clause 52.212-2, Evaluation - Commercial Items x. In accordance with FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items, offerors must complete annual representations and certifications on- line at https://www.sam.gov/portal/public/SAM/. xi. FAR clause 52.212-4, Contract Terms and Conditions - Commercial Items applies to this acquisition. xii. FAR clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items applies to this Acquisition. Additional FAR Clauses include: FAR clause 52.204-10, Reporting Executive Compensation and First-Tier Subcontract Awards (JUL2013) (Pub.L. 109-282) (31 U.S.C. 6101 note). FAR clause 52.223-18, Encouraging Contractor Policies to Ban Text Messaging while Driving (AUG2011). FAR clause 52.225-13, Restrictions on Certain Foreign Purchases (JUN 2008) (E.O.'s, proclamations, and statutes administered by the Office of Foreign Assets Control of the Department of the Treasury). FAR clause 52.232-33, Payment by Electronic Funds Transfer-System for Award Management (JUL2013) (31 U.S.C. 3332). xiii. All responses must be received no later than 7:30 a.m. Eastern Standard Time (EST), May 24, 2018; and must reference synopsis number NIHHL201800009, may be submitted to the National, Heart, Lung and Blood Institute, COAC Services Branch, Office of Acquisitions, Office of Management, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell, Contracting Officer. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. " All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency." 1. Name of Contracting Organization; 2. Solicitation number; 3. Contract Type; 4. Total Contract Value and Discounts; 5. Description of Requirement; 6. North American Industry Classification System (NAICS) Code; and 7. DUNS, TIN or EIN Number. xv. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency. Offers are due by 7:30 A.M. Eastern Time (EST) on May 24, 2018. Dorothy Maxwell, Contracting Officer can be reached at (301) 827-7729 regarding any questions regarding Solicitation Number: NIHHL201800009. Quotations shall not be deemed received by the Government until the quotation is entered into the e-mail address inbox set forth above. Faxed proposals will NOT be accepted. Offerors must complete annual representations and certifications on-line at https://www.sam.gov/portal/public/SAM/.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NIHHL201800009/listing.html)
- Place of Performance
- Address: Contractor's Site, United States
- Record
- SN04928000-W 20180520/180518230534-9a8c120b2e5f0f6908c69f87fecc4644 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |